These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
901 related articles for article (PubMed ID: 28893690)
1. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Wright H; Bonomo RA; Paterson DL Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690 [TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
3. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Bader MS; Loeb M; Leto D; Brooks AA Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743 [TBL] [Abstract][Full Text] [Related]
4. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Sharma R; Park TE; Moy S Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862 [TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Liscio JL; Mahoney MV; Hirsch EB Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591 [TBL] [Abstract][Full Text] [Related]
7. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases. Meschiari M; Asquier-Khati A; Tiseo G; Luque-Paz D; Murri R; Boutoille D; Falcone M; Mussini C; Tattevin P; Int J Antimicrob Agents; 2024 Jul; 64(1):107186. PubMed ID: 38688353 [TBL] [Abstract][Full Text] [Related]
8. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397 [TBL] [Abstract][Full Text] [Related]
9. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives. Karvouniaris M; Pontikis K; Nitsotolis T; Poulakou G Expert Rev Anti Infect Ther; 2021 Jul; 19(7):825-844. PubMed ID: 33270485 [No Abstract] [Full Text] [Related]
10. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Karaiskos I; Galani I; Souli M; Giamarellou H Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244 [TBL] [Abstract][Full Text] [Related]
11. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
12. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Bush K Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989 [TBL] [Abstract][Full Text] [Related]
13. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ; J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471 [TBL] [Abstract][Full Text] [Related]
14. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. Jean SS; Gould IM; Lee WS; Hsueh PR; Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660 [TBL] [Abstract][Full Text] [Related]
15. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients. Barbier F; Hraiech S; Kernéis S; Veluppillai N; Pajot O; Poissy J; Roux D; Zahar JR; Ann Intensive Care; 2023 Jul; 13(1):65. PubMed ID: 37462830 [TBL] [Abstract][Full Text] [Related]
16. Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study. Strich JR; Mishuk A; Diao G; Lawandi A; Li W; Demirkale CY; Babiker A; Mancera A; Swihart BJ; Walker M; Yek C; Neupane M; De Jonge N; Warner S; Kadri SS; Ann Intern Med; 2024 May; 177(5):559-572. PubMed ID: 38639548 [TBL] [Abstract][Full Text] [Related]
17. [New β‑lactam antibiotics and β‑lactamase inhibitors against multidrug-resistant Gram-negative bacteria]. Mischnik A; Lübbert C; Mutters NT Internist (Berl); 2018 Dec; 59(12):1335-1343. PubMed ID: 30264191 [TBL] [Abstract][Full Text] [Related]